Ming Zi Chen

ATI Technologies, Inc. designs, makes and, sells graphics accelerators and multimedia solutions. It offers visual and graphics processors for displaying images on personal computer monitors. It also supplies graphics, video and, multimedia products for desktop, workstation & notebook personal computers, digital televisions, cell phones, and game consoles. The company sells its products through personal computer original equipment manufacturers, system integrators, add-in board manufacturers, retail stores & consumer electronics manufacturers in North America, Europe and Asia-Pacific. The firm was founded by Kwok Yuen Ho in 1985 and is located in Markham, Canada.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Case Western Reserve University provides educational services. It offers a variety of undergraduate degree courses and graduate and professional options such as arts and sciences, dentistry, engineering, law, management, medicine, nursing, social work, and more. The firm also offers dual-degree programs. The company was founded in 1826 and is headquartered in Cleveland, OH.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs.

CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China.

Silicon Therapeutics LLC operates as an integrated computational drug discovery company that focuses on developing novel medicines for diseases. Its INSITE platform closely represents the dynamical nature of targets using all-atom simulations. The firm has offices in Boston and Shanghai. The company was founded by Lijun Sun, Peiqi Sun, Elliot L. Chaikof, and Finith Jernigan, III in 2016 and is headquartered in Boston, MA.

Abbisko Therapeutics Co., Ltd. engages in the research and development of biomedicine and biotechnology. Its business includes technology transfer, technical advisory, and technical services. The company was founded on April 12, 2016 and is headquartered in Shanghai, China.

Harbour Biomed Shanghai Co. Ltd. engages in the development of therapeutics for cancer, especially in immuno-oncology. The company is headquartered in Shanghai, China.

Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China.

InSilico Medicine Hong Kong Ltd. operates as bioinformatics company, which utilizes advances in genomics, big data analysis and deep learning for silico drug discovery and drug repurposing for aging and age-related diseases. The company was founded by Alex Zhavoronkov and is headquartered in Hong Kong.

Antengene Corporation Co., Ltd. operates as a holding company. It engages in clinical development of drug candidates. The company was founded on June 15, 2016 and is headquartered in Shanghai, China.

Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.

The Alliance for Artificial Intelligence in Healthcare (AAIH) is an advocacy organization that aims to improve patient outcomes and minimize healthcare costs through the discovery, development, and delivery of better solutions. The private company is based in Long Island City, NY, and was founded by Brandon Allgood. The organization fosters creativity, collaboration, and knowledge sharing among its members, who come from diverse backgrounds in science, math, technology, and healthcare. AAIH is focusing on two primary practice areas in 2023: developing a comprehensive framework for digitizing IND and addressing core challenges in data accessibility through a real-world data registry.

Deep Longevity Ltd. develops artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system and psychological levels. Its products include longevity cloud, recommendation engines, deep aging clocks and age metric reports. The company was founded in 2020 by Alex Zhavoronkov and is headquartered in San Diego, CA.

LongeVC is a venture capital firm, founded in 2020 by Garri Zmudze, Ilya Suharenko, Sergey Jakimov. The firm is headquartered in Lugano, Switzerland.

Part of Wuxi Biologics (Cayman), Inc., WuXi Vaccines Ireland Ltd. discovers, develops and manufactures human vaccines. The company is based in Dundalk, Ireland. The CEO of the Irish company is Jian Dong.

Insilico Medicine IP Ltd. engages in the investment of drug discovery and drug development through the deployment of new artificial intelligence technologies. The company was founded on June 21, 2019 and is headquartered in Hong Kong.

Zion Pharma Ltd. is a private, Chinese clinical stage biotech company founded in 2018. The company's research operations are located in mainland China and they have additional research operations elsewhere. The company is based in China and has subsidiaries in the country. The company is focused on developing novel, small molecule, anti-tumoral agents using an innovative drug discovery approach. Zion Pharma is capitalizing on its dmpk expertise to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (atm), kirsten rat sarcoma (kras g12d) and smarca2 (brm).

HTDK Medical Holdings Ltd. operates as an investment holding company. It is principally engaged in providing product commercial solutions in medical device and consumer healthcare product sectors. The company specializes in medical device enterprises which cover the diagnosis, orthopedics, ophthalmology, cardiovascular and other indications. The company was founded on July 9, 2021 and is headquartered on Shanghai, China.

Marble Therapeutics, Inc. develops gene therapies. The company is based in Boston, MA.